OWC Pharmaceutical, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, reported the last healthy volunteer in its first ever safety study of cannabis-based topical ointment, was recently admitted in trial which is being conducted at Sheba Medical Center, Tel Hashomer, Israel.

"We are extremely pleased with the progress on this trial. Recruiting has now been completed and we expect to complete the trial by the end of December," Mordechai Bignitz, OWC Pharmaceutical CEO said. "We recently had the opportunity to present our innovative research and pipeline progress to investors and potential business partners at the MJBizCon in Las Vegas. We are evaluating a number of potential avenues to accelerate our development as we strongly believe that our innovative dosage forms, delivery platforms and our clinical research can unlock the potential of cannabis-based treatments and improve patients' quality of life". 

-----------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.